Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the dose response of SyB D-0701 for preventing nausea
and emesis associated with radiotherapy (fractionated/localized irradiation) in cancer
patients scheduled to receive radiotherapy (fractionated/localized irradiation) alone.